Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674750 | 1.00 | APP (0.63) | APPIDO1F10MAOBMAOA | |
| SCHEMBL5708187 | 0.98 | APP (0.61) | APPIDO1F10MAOBMAOA | |
| SCHEMBL5708184 | 0.96 | APP (0.59) | APPIDO1F10MAOBMAOA | |
| SCHEMBL314468 | 0.89 | APP (0.63) | APPMAOBMAOALCKCYP4F2 | |
| SCHEMBL1548932 | 0.86 | F10 (0.62) | APPF10MAOBMAOALCK | |
| SCHEMBL5708191 | 0.85 | APP (0.59) | APPMAOBMAOALCKCYP4F2 | |
| SCHEMBL32665169 | 0.84 | APP (0.59) | APPF10MAOBMAOALCK | |
| SCHEMBL9060683 | 0.84 | APP (0.64) | APPIDO1MAOBMAOA | |
| Formaldehyde SCHEMBL27783224 | 0.84 | NR4A2 (0.61) | APPMAOBMAOALCKCYP4F2 | |
| SCHEMBL15761340 | 0.82 | BCHE (0.70) | APPF10MAOBMAOALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023232966-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-12-07 | — | — | WO | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-108774200-A | The crystalline composites of compound, preparation method and its purposes for being used to prepare drug | 贝林格尔·英格海姆维特梅迪卡有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-104470908-A | Crystalline complex of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (beta-D-glucopyranos-1-yl) -benzene, method for preparing same and use thereof for preparing a medicament | BOEHRINGER INGELHEIM VETMED | 2015-03-25 | — | — | CN | disclosed |
| CN-102351918-B | Glucopyranosyl-substituted benzonitrile derivatives and pharmaceutical compositions containing the same | BOEHRINGER INGELHEIM INT | 2015-03-04 | — | — | CN | disclosed |
| CN-104353077-A | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | BOEHRINGER INGELHEIM INT | 2015-02-18 | — | — | CN | disclosed |
| CN-104288166-A | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | BOEHRINGER INGELHEIM INT | 2015-01-21 | — | — | CN | disclosed |
| US-20060257987-A1 | Ppar modulators | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-09-14 | — | — | US | disclosed |
| EP-1660428-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1585726-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005019151-A1 | PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-6849649-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. (US) | 2005-02-01 | — | — | US | disclosed |
| WO-2004063155-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | APP 3135/4885IDO1 4127/4885F10 1040/4885 |
| US-20060205744-A1 | Fused heterocyclic derivatives as ppar modulators | PPARA, PPARG, PPARD | APP 4140/4885IDO1 4005/4885F10 2362/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | APP 3135/4885IDO1 4127/4885F10 1040/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | APP 3135/4885IDO1 4127/4885F10 1040/4885 |
| US-20250320227-A1 | MACROCYCLIC OREXIN RECEPTOR AGONISTS AND USES THEREOF | HCRTR1, HCRTR2, NPY1R | APP 420/4885IDO1 1116/4885F10 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.